# EDGAR Filing Document

**Accession Number:** 0001661181
**File Stem:** 0001193125-25-175468
**Filing Date:** 2025-8
**Character Count:** 16477
**Document Hash:** 3afbaa1ae9dd7afd515ba26bb63c603a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-175468.hdr.sgml**: 20250807

**ACCESSION NUMBER**: 0001193125-25-175468

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20250807

**DATE AS OF CHANGE**: 20250807

**EFFECTIVENESS DATE**: 20250807

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Organogenesis Holdings Inc.
- **CENTRAL INDEX KEY:** 0001661181
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-289367
- **FILM NUMBER:** 251194576

**BUSINESS ADDRESS:**
- **STREET 1:** 85 DAN ROAD
- **CITY:** CANTON
- **STATE:** MA
- **ZIP:** 02021
- **BUSINESS PHONE:** 781-575-0775

**MAIL ADDRESS:**
- **STREET 1:** 85 DAN ROAD
- **CITY:** CANTON
- **STATE:** MA
- **ZIP:** 02021

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Avista Healthcare Public Acquisition Corp.
- **DATE OF NAME CHANGE:** 20151215

**AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON AUGUST 7, 2025** 

**REGISTRATION NO. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## ORGANOGENESIS HOLDINGS INC.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **98-1329150** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**85 Dan Road** 

**Canton, MA 02021** 

**(Address of principal executive offices, including zip code)** 

**Organogenesis Holdings Inc. 2018 Equity Incentive Plan** 

**(Full title of the plan)** 

**Lori Freedman** 

**Chief Administrative and Legal Officer** 

**Organogenesis Holdings Inc.** 

**85 Dan Road** 

**Canton, MA 02021** 

**(Name and address of agent for service)** 

**(781) 575-0775** 

**(Telephone number, including area code, of agent for service)** 

***Copies to:***

**William R. Kolb** 

**Ryan M. Rourke Reed** 

**Foley Hoag LLP** 

**155 Seaport Boulevard** 

**Boston, Massachusetts 02210** 

**Telephone: (617) 832-1000** 

**Telecopy: (617) 832-7000** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☑ |
| Non-accelerated filer | ☐ | Smaller Reporting Company | ☐ |
|  |  | Emerging Growth Company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

Organogenesis Holdings Inc. (the "Registrant") is filing this Registration Statement on Form S-8 (this "Registration Statement") to register an additional 15,900,000 shares of its Class A common stock, par value $0.0001 per share, that may be issued and sold under the Organogenesis Holdings Inc. 2018 Equity Incentive Plan, as amended (the "Plan"), following the amendment to the Plan that was approved by the Registrant's stockholders at its annual meeting on June 20, 2024. This Registration Statement is submitted in accordance with General Instruction E to Form S-8 regarding registration of additional securities, and pursuant to that instruction, the contents of the Registration Statements on Form S-8 (File No. 333-229601 and File No. 333-268736) filed with the Securities and Exchange Commission on [February 11, 2019](http://www.sec.gov/Archives/edgar/data/1661181/000119312519033971/d704029ds8.htm) and [December 9, 2022](http://www.sec.gov/Archives/edgar/data/1661181/000119312522301841/d424717ds8.htm), respectively, are incorporated herein by reference.

**Part II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 8. Exhibits.** 

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| &nbsp;&nbsp;&nbsp;&nbsp;4.1 | [Certificate of Incorporation of ORGO (incorporated by reference to Exhibit 3.1 to the Company's Registration Statement on Form S-3/A (File No. 333-233621) filed with the SEC on September 16, 2019)](http://www.sec.gov/Archives/edgar/data/1661181/000119312519245823/d772464dex31.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.2 | [Certificate of Amendment of Certificate of Incorporation of Organogenesis Holdings Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K (File No. 001-37906) filed with the SEC on June 27, 2022)](http://www.sec.gov/Archives/edgar/data/0001661181/000119312522182860/d299566dex31.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.3 | [Certificate of Designations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.3 to the Company's Quarterly Report on Form 10-Q (File No. 001-37906) filed with the SEC on November 12, 2024)](http://www.sec.gov/Archives/edgar/data/1661181/000095017024125431/orgo-ex3_3.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.4 | [Bylaws of ORGO (incorporated by reference to Exhibit 3.2 to the Company's Registration Statement on Form S-3/A (File No. 333-233621) filed with the SEC on September 16, 2019)](http://www.sec.gov/Archives/edgar/data/1661181/000119312519245823/d772464dex32.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.4+ | [2018 Equity Incentive Plan (as amended) (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 001-37906) filed with the SEC on June 21, 2024)](http://www.sec.gov/Archives/edgar/data/1661181/000095017022016142/orgo-ex10_1.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;5.1\* | [Opinion of Foley Hoag LLP](d99134dex51.htm) |
| 23.1\* | [Consent of RSM US LLP](d99134dex231.htm) |
| 23.2\* | [Consent of Foley Hoag LLP (included in the opinion filed as Exhibit 5.1)](d99134dex51.htm) |
| 24.1\* | [Power of Attorney (included on the signature page hereto)](d99134ds8.htm#sig) |
| 107\* | [Filing Fee Table](d99134dexfilingfees.htm) |

---

**\*** Filed herewith. 

+ Indicates management contract or compensatory plan.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Canton, Commonwealth of Massachusetts, on August 7, 2025.

---

| | |
|:---|:---|
| ORGANOGENESIS HOLDINGS INC. | ORGANOGENESIS HOLDINGS INC. |
| By: | /s/ Gary S. Gillheeney, Sr. |
|  | Gary S. Gillheeney, Sr.<br> President and Chief Executive Officer |

---

**POWER OF ATTORNEY** 

We, the undersigned officers and directors of Organogenesis Holdings Inc., hereby severally constitute and appoint each of Gary S. Gillheeney, Sr. and David Francisco, our true and lawful attorneys-in-fact, with full power to them in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8 (including any post-effective amendments thereto), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| Signature | Title | Date |
| /s/ Gary S. Gillheeney, Sr.<br> Gary S. Gillheeney, Sr. | Chief Executive Officer, President and Director<br>(Principal Executive Officer) | August 7, 2025 |
| /s/ David Francisco<br> David Francisco | Chief Financial Officer<br>(Principal Financial and<br>Accounting Officer) | August 7, 2025 |
| /s/ Robert Ades<br> Robert Ades | Director | August 7, 2025 |
| /s/ Michael J. Driscoll<br> Michael J. Driscoll | Director | August 7, 2025 |
| /s/ Prathyusha Duraibabu<br> Prathyusha Duraibabu | Director | August 7, 2025 |
| /s/ Jon Giacomin<br> Jon Giacomin | Director | August 7, 2025 |
| /s/ Michele Korfin<br> Michele Korfin | Director | August 7, 2025 |
| /s/ Arthur S. Leibowitz<br> Arthur S. Leibowitz | Director | August 7, 2025 |

---

------

---

| | | |
|:---|:---|:---|
| /s/ Garrett Lustig<br> Garrett Lustig | Director | August 7, 2025 |
| /s/ Glenn H. Nussdorf<br> Glenn H. Nussdorf | Director | August 7, 2025 |
| /s/ Gilberto Quintero<br> Gilberto Quintero | Director | August 7, 2025 |

---

## Exhibit 5.1

**Exhibit 5.1** 

---

| | |
|:---|:---|
| ![LOGO](g99134g0805073627011.jpg)  | Seaport West<br> 155 Seaport Boulevard<br> Boston, MA 02210-2600<br>617 832 1000 *main*<br> 617 832 7000 *fax* |

---

August 7, 2025

Organogenesis Holdings Inc.

85 Dan Road

Canton, MA 02021

Re: <u>Registration Statement on Form S-8</u> 

To the Addressees:

We are familiar with the Registration Statement on Form S-8 (the "**Registration Statement**") being filed by Organogenesis Holdings Inc., a Delaware corporation (the "**Company**"), with the Securities and Exchange Commission (the "**Commission**") under the Securities Act of 1933, as amended (the "**Securities Act**"), on the date hereof. The Registration Statement relates to the offer and sale by the Company of up to 15,900,000 shares (the "**Shares**") of its Class A common stock, par value $0.0001 per share ("**Common Stock**"), issuable under the Company's 2018 Equity Incentive Plan (as amended through June 20, 2024, the "**2018 Plan**").

In arriving at the opinions expressed below, we have examined the Certificate of Incorporation and Bylaws of the Company, each as amended to date, the records of meetings and consents of the Company's Board of Directors, or committees thereof, records of the proceedings of its stockholders, and the 2018 Plan, each as provided to us by the Company, and the Registration Statement.

In addition, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. In our examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to authentic original documents of all documents submitted to us as copies and the due authorization, execution and delivery of all documents by all persons other than the Company, where authorization, execution and delivery are prerequisites to the effectiveness of such documents. We have also made such investigations of law as we have deemed appropriate as a basis for the opinions expressed below.

We have assumed that the purchase price or other consideration to be received by the Company for the Shares will be valid consideration equal to or in excess of the par value thereof.

In rendering the opinion expressed below, we express no opinion other than as to the Delaware General Corporation Law.

On the basis of the foregoing, it is our opinion that the Shares, when issued and delivered in accordance with the terms of the 2018 Plan and the awards thereunder against the Company's receipt of the purchase price or other consideration therefor, will be validly issued, fully paid and non-assessable.

This opinion is to be used only in connection with the offer and sale of the Shares while the Registration Statement is in effect.

This opinion is being delivered solely for the benefit of the Company and such other persons as are entitled to rely upon it pursuant to the applicable provisions of the Securities Act. This opinion may not be used, quoted, relied upon or referred to for any other purpose, nor may it be used, quoted, relied upon or referred to by any other person, for any purpose, without our prior written consent.

------

This opinion is based upon currently existing statutes, rules and regulations and judicial decisions and is rendered as of the date hereof, and we disclaim any obligation to advise you of any change in any of the foregoing sources of law or subsequent developments in law or changes in facts or circumstances which might affect any matters or opinions set forth herein.

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.

This opinion letter shall be interpreted in accordance with the Core Opinion Principles jointly issued by the Committee on Legal Opinions of the American Bar Association's Business Law Section and the Working Group on Legal Opinions Foundation as published in 74 Business Lawyer 815 (2019).

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| FOLEY HOAG LLP | FOLEY HOAG LLP |
| By: | /s/ Ryan M. Rourke Reed |
|  | a Partner |

---

## Exhibit 23.1

**Exhibit 23.1** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the incorporation by reference in this Registration Statement on Form S-8 of Organogenesis Holdings Inc. of our reports dated February 27, 2025, relating to the consolidated financial statements and the effectiveness of internal control over financial reporting of Organogenesis Holdings Inc., appearing in the Annual Report on Form 10-K of Organogenesis Holdings Inc. for the year ended December 31, 2024.

/s/ RSM US LLP

Boston, Massachusetts

August 7, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Organogenesis Holdings Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Class A Common Stock, $0.0001 par value per share | Other | 15900000 | $4.485 | $71311500.00 | 0.0001531 | $10917.79 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $71311500.00  |  | $10917.79  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $10917.79  |

---

 **Offering Note** <br>

<sup>1</sup> (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement on Form S-8 (the "Registration Statement") shall also cover any additional shares of the Registrant's Class A common stock, $0.0001 par value per share (the "Common Stock") that become issuable under the Registrant's 2018 Equity Incentive Plan (as amended through June 20, 2024) (the "Plan") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration that increases the number of the Registrant's outstanding shares of Common Stock. (2) This Registration Statement covers 15,900,000 shares of the Registrant's Common Stock, which are issuable pursuant to the Plan. (3) Estimated in accordance with Rule 457(c) and (h) under the Securities Act solely for the purpose of calculating the registration fee on the basis of $4.485, the average of the high and low prices of the Registrant's Common Stock as reported on The Nasdaq Capital Market on August 1, 2025, which date is within five business days prior to the filing of this Registration Statement.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---